Superconducting head MRI approved for use in critical care environments.
Evry(tm) Point-of-Care MRI Courtesy: Synaptive Medical
Robotic surgical visualization company Synaptive Medical secured 510(k) clearance from the U.S. Food & Drug Administration today for Evry™, its superconducting, head MRI. The system is designed provide diagnostic imaging capabilities at the point-of-care in critical-care settings.
According to a company statement, Evry will be able detect potential COVID-19 complications, ischemic stroke, neurological damage, or potential head trauma. The system will soon be commercially available in the United States, and it will be operational both independently and with a variety of outside systems.
“As medical professionals, our goal is to utilize every tool at our disposal that will improve outcomes for our patients in a variety of situations,” said Gustavo Pradilla, M.D., chief of neurosurgery at Grady Memorial Hospital. “With the availability of Evry in the United States, we will now be able to provide critical diagnostic information in settings beyond where traditional MRIs are offered, which can significantly expedite the speed at which we make actionable decisions that positively impact patient care.”
Evry’s mid-field 0.5T superconducting magnet can be housed in a smaller apparatus than traditional higher-field MRIs, reducing the amount of floor space it takes up. It also include pre-defined imaging protocols, automated series planning, including volume selection, a detachable stretcher to support bedside transfers, and a multi-channel head coil with patient-specific customized fitting that can maximize image quality.
Additionally, as a smaller system, delivery is easier – there’s no need for rigging or cranes. Cost is also reduced, company officials said, because it doesn’t require yearly cryogen refills, a cryogen pipe, and reinforced flooring.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.